?? ?????? ???????????? ??????? ?????? ????????:
U.K. Atrial Fibrillation Devices Market to surpass USD 2.063.9 million by 2031 from USD 706.1 million in 2021 at a CAGR of 11.3% in the coming years, i.e., 2021-2031.
??????? ?????? ???????????? ??????????: One of the most prevalent heart arrhythmias, atrial fibrillation affects millions of people globally. Atrial fibrillation is becoming more common in the UK, especially in the elderly population. The need for efficient atrial fibrillation therapy and management alternatives is growing along with the prevalence of risk factors such as obesity, diabetes, and hypertension.
???????????? ?? ?? ?????? ??????????: The diagnosis, treatment, and management of atrial fibrillation have been completely transformed by technological developments in equipment. When compared to conventional treatment techniques, innovative devices such as implantable cardiac monitors (ICMs), cardiac ablation catheters, left atrial appendage closure (LAAC) devices, and cardiac rhythm management (CRM) devices offer better accuracy, efficacy, and patient outcomes.
?.?. ?????? ???????????? ??????? ?????? ?? ??????? ????????? ?? ?????? ????:
· England Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
· Northern Ireland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
· Scotland Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
· Wales Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR
?????????? ?????? ??? ????????? ???????? ??????????: Minimally invasive procedures such as catheter ablation and left atrial appendage closure have gained popularity in the management of atrial fibrillation, offering patients shorter hospital stays, faster recovery times, and reduced risk of complications compared to open surgical procedures. The adoption of minimally invasive techniques is driving the demand for advanced AF devices in the UK market.
??? ?????????:
· Abbott
· Boston Scientific Corporation,
· Biotronik,
· Cardinal Health,
· GE Healthcare,
· Medtronic Plc,
· Siemens Healthineers AG,
· W. L. Gore & Associates, Inc.,
· Hansen Medical Inc,
· Cardiofocus Inc
??? ?? ???????? ?? ???????? ???? ??? ?????????? ???????: Due to the increased risk of stroke and systemic embolism in patients with atrial fibrillation, stroke prevention is a top focus in the treatment of AF. In patients with non-valvular atrial fibrillation, left atrial appendage closure devices, such WATCHMANTM and AmplatzerTM AmuletTM, provide an option to oral anticoagulant medication for stroke prevention, lowering the risk of bleeding issues related to long-term anticoagulation.
????????? ??? ?????? ???????: A greater number of people are becoming aware of atrial fibrillation, which is driving the market for AF devices in the UK. The demand for less invasive treatment options is also driving this increase. Opportunities for the future include the creation of individualized treatment plans, next-generation AF devices, and digital health tools for atrial fibrillation patients that allow for remote patient monitoring and management.
????? ???????? ??? ????????? ?????????: Innovation is fueled by cooperation and strategic alliances between producers of medical devices, healthcare providers, and academic institutions. These alliances also make it easier to develop and market novel atrial fibrillation devices. The goals of collaborative initiatives are to raise the bar for atrial fibrillation patient treatment, address unmet clinical requirements, and enhance patient outcomes.
